GlassScriptPhysician profile
Ulrich Luft
NPI 1831115229
$18,192.44
in general payments reported to CMS, 2019-2025
29 companies · $2,514 in 2025
The $2,514 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $531 · 2021: $651 · 2022: $411 · 2023: $1,985 · 2024: $713 · 2025: $2,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,398 · Travel and Lodging: $1,351 · Entertainment: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,398.01 |
| Travel and Lodging | $1,351.42 |
| Entertainment | $462.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $4,347.28 | 2019-2024 | Gore Cardioform Septal Occluder |
| Edwards Lifesciences Corporation | $3,439.97 | 2019-2025 | Evoque, Pascal, Sapien 3 Ultra Resilia |
| Abbott Laboratories | $2,231.59 | 2019-2025 | Triclip, Cardiomems, Mitraclip |
| Boston Scientific Corporation | $2,224.26 | 2019-2025 | Watchman Access System, Watchman, Watchman Flx |
| Cardiva Medical, INC. | $681.42 | 2024-2025 | Savvywire, Optowire, Other |
| Philips North America LLC | $668.99 | 2019-2020 | |
| Medtronic Vascular, INC. | $666.08 | 2019-2020 | |
| Opsens INC. | $613.40 | 2022-2023 | Optowire |
| Pfizer INC. | $502.27 | 2019-2025 | |
| Abiomed | $499.52 | 2019-2025 | |
| Medtronic, INC. | $463.01 | 2021-2023 | Hawkone |
| Novartis Pharmaceuticals Corporation | $274.63 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $264.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.84 | 2019-2025 | Jardiance |
| Amgen INC. | $229.07 | 2019-2025 | Repatha, Repatha |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $181.16 | 2019-2023 | Camzyos |
| Cardiovascular Systems INC. | $140.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $86.39 | 2019 | |
| Alnylam Pharmaceuticals INC. | $83.90 | 2023-2025 | Onpattro, Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $78.55 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $66.81 | 2024-2025 | Farxiga, Wainua |
| Cvrx, INC. | $45.87 | 2024-2025 | Barostim Neo System |
| Cardinal Health 200 LLC | $43.38 | 2019 | |
| Novo Nordisk INC | $29.30 | 2025 | Wegovy |
| Inspire Medical Systems, INC. | $24.69 | 2025 | Inspire |
| Cathworks, INC. | $19.41 | 2023 | Ffrangio |
| Surmodics, INC. | $18.99 | 2023 | Pounce Venous Thrombectomy System, Sublime 014 Rx Pta Balloon Dilatation Catheter, Sublime Radial Access 018 Rx Pta Dilatation Catheter |
| Biotronik INC. | $15.16 | 2020 | |
| Esperion Therapeutics, INC. | $15.13 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ulrich Luft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.